Back to Journals » OncoTargets and Therapy » Volume 9

Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients

Authors Li M, He Q, Li M, Luo F, Guan Y

Received 9 October 2015

Accepted for publication 14 January 2016

Published 9 March 2016 Volume 2016:9 Pages 1291—1302

DOI https://doi.org/10.2147/OTT.S80635

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Dekuang Zhao

Peer reviewer comments 2

Editor who approved publication: Professor Daniele Santini


Meng-Jiao Li, Qing He, Mei Li, Feng Luo, Yong-Song Guan

Department of Oncology, Center of Oncology, West China Hospital of Sichuan University, Chengdu, People’s Republic of China

Abstract: Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer. Conventional treatment options have limited efficacy because most cases are in the advanced stage at the time of diagnosis. In recent years, gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has shown its good antitumor activities in treating NSCLC in a number of studies. This paper reviews its role in the targeted treatment of NSCLC in Chinese patients.

Keywords: pulmonary carcinoma, therapy, EGFR-TK inhibitor, status, People’s Republic of China
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]